Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NO_LONGER_AVAILABLE
Study Classification
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This protocol provides ongoing access to triheptanoin for patients who did complete an initial pilot protocol, and provides the opportunity to collect long-term safety data from patients treated with triheptanoin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
NCT02021526
Glucose Transporter Type 1 Deficiency Syndrome
Glut1 Deficiency Syndrome
WITHDRAWN
PHASE1/PHASE2
Treatment Development of Triheptanoin (G1D)
NCT03041363
Epilepsy
GLUT1DS1
Glut1 Deficiency Syndrome 1, Autosomal Recessive
+4 more
COMPLETED
PHASE1
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
NCT02036853
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
COMPLETED
PHASE2
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
NCT02018315
Glucose Transporter Type 1 Deficiency Syndrome
GLUT1 Deficiency Syndrome
COMPLETED
PHASE1
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
NCT03181399
GLUT1DS1
Epilepsy
Glut1 Deficiency Syndrome 1, Autosomal Recessive
+4 more
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Only patients who completed the initial pilot study were eligible. The study is ongoing with these patients only.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Glut1 Deficiency Syndrome
Glucose Transporter Type 1 Deficiency Syndrome
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triheptanoin
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
C7 oil
Heptanoate
heptanoic acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients enrolled in the pilot trial (UTSW 122010-186)
Exclusion Criteria
* Subjects who did not complete the pilot trial (UTSW 122010-186)
Minimum Eligible Age
1 Month
Maximum Eligible Age
28 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juan Pascual
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan Pascual
Associate Professor, Director of the Rare Brain Disorders Program
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan M Pascual, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UT Southwestern Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT Southwestern Medical Center
Dallas, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab. 2013 Feb;33(2):175-82. doi: 10.1038/jcbfm.2012.151. Epub 2012 Oct 17.
Reference Type
BACKGROUND
Marin-Valencia I, Good LB, Ma Q, Duarte J, Bottiglieri T, Sinton CM, Heilig CW, Pascual JM. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype. Neurobiol Dis. 2012 Oct;48(1):92-101. doi: 10.1016/j.nbd.2012.04.011. Epub 2012 Apr 23.
Reference Type
BACKGROUND
Marin-Valencia I, Roe CR, Pascual JM. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol Genet Metab. 2010 Sep;101(1):9-17. doi: 10.1016/j.ymgme.2010.05.004. Epub 2010 Jun 9.
Reference Type
BACKGROUND
Wang D, Sands T, Tang M, Monani U, De Vivo D. Glucose Transporter Type 1 Deficiency Syndrome. 2002 Jul 30 [updated 2025 Mar 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from http://www.ncbi.nlm.nih.gov/books/NBK1430/
Reference Type
BACKGROUND
Perez-Duenas B, Prior C, Ma Q, Fernandez-Alvarez E, Setoain X, Artuch R, Pascual JM. Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy failure syndrome. Arch Neurol. 2009 Nov;66(11):1410-4. doi: 10.1001/archneurol.2009.236.
Reference Type
BACKGROUND
Jeffrey FM, Marin-Valencia I, Good LB, Shestov AA, Henry PG, Pascual JM, Malloy CR. Modeling of brain metabolism and pyruvate compartmentation using (13)C NMR in vivo: caution required. J Cereb Blood Flow Metab. 2013 Aug;33(8):1160-7. doi: 10.1038/jcbfm.2013.67. Epub 2013 May 8.
Reference Type
BACKGROUND
Xu F, Liu P, Pascual JM, Xiao G, Lu H. Effect of hypoxia and hyperoxia on cerebral blood flow, blood oxygenation, and oxidative metabolism. J Cereb Blood Flow Metab. 2012 Oct;32(10):1909-18. doi: 10.1038/jcbfm.2012.93. Epub 2012 Jun 27.
Reference Type
BACKGROUND
Pascual JM, Campistol J, Gil-Nagel A. Epilepsy in inherited metabolic disorders. Neurologist. 2008 Nov;14(6 Suppl 1):S2-S14. doi: 10.1097/01.nrl.0000340787.30542.41.
Reference Type
BACKGROUND
Wang D, Yang H, Shi L, Ma L, Fujii T, Engelstad K, Pascual JM, De Vivo DC. Functional studies of the T295M mutation causing Glut1 deficiency: glucose efflux preferentially affected by T295M. Pediatr Res. 2008 Nov;64(5):538-43. doi: 10.1203/PDR.0b013e318184d2b5.
Reference Type
BACKGROUND
Gomez Lado C, Couce Pico ML, Sanchez-Salmon A, Pascual JM. [Glucose transporter type 1 deficiency: a treatable neuro-metabolic disorder]. An Pediatr (Barc). 2008 Sep;69(3):285-6. doi: 10.1157/13125831. No abstract available. Spanish.
Reference Type
BACKGROUND
Pascual JM, Wang D, Yang R, Shi L, Yang H, De Vivo DC. Structural signatures and membrane helix 4 in GLUT1: inferences from human blood-brain glucose transport mutants. J Biol Chem. 2008 Jun 13;283(24):16732-42. doi: 10.1074/jbc.M801403200. Epub 2008 Apr 3.
Reference Type
BACKGROUND
Pascual JM, Wang D, Hinton V, Engelstad K, Saxena CM, Van Heertum RL, De Vivo DC. Brain glucose supply and the syndrome of infantile neuroglycopenia. Arch Neurol. 2007 Apr;64(4):507-13. doi: 10.1001/archneur.64.4.noc60165. Epub 2007 Feb 12.
Reference Type
BACKGROUND
Pascual JM. [Glucose transport hereditary diseases]. Med Clin (Barc). 2006 Nov 11;127(18):709-14. doi: 10.1157/13095099. Spanish.
Reference Type
BACKGROUND
Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC. A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet. 2006 Apr 1;15(7):1169-79. doi: 10.1093/hmg/ddl032. Epub 2006 Feb 23.
Reference Type
BACKGROUND
Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, De Vivo DC. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005 Jan;57(1):111-8. doi: 10.1002/ana.20331.
Reference Type
BACKGROUND
Pascual JM, Lecumberri B, Wang D, Yang R, Engelstad K, De Vivo DC. [Type 1 glucose transporter (Glut1) deficiency: manifestations of a hereditary neurological syndrome]. Rev Neurol. 2004 May 1-15;38(9):860-4. Spanish.
Reference Type
BACKGROUND
Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC. GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol. 2004 May;150(5):627-33. doi: 10.1530/eje.0.1500627.
Reference Type
BACKGROUND
Wang D, Pascual JM, Iserovich P, Yang H, Ma L, Kuang K, Zuniga FA, Sun RP, Swaroop KM, Fischbarg J, De Vivo DC. Functional studies of threonine 310 mutations in Glut1: T310I is pathogenic, causing Glut1 deficiency. J Biol Chem. 2003 Dec 5;278(49):49015-21. doi: 10.1074/jbc.M308765200. Epub 2003 Sep 16.
Reference Type
BACKGROUND
Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002 Oct;52(4):458-64. doi: 10.1002/ana.10311.
Reference Type
BACKGROUND
Iserovich P, Wang D, Ma L, Yang H, Zuniga FA, Pascual JM, Kuang K, De Vivo DC, Fischbarg J. Changes in glucose transport and water permeability resulting from the T310I pathogenic mutation in Glut1 are consistent with two transport channels per monomer. J Biol Chem. 2002 Aug 23;277(34):30991-7. doi: 10.1074/jbc.M202763200. Epub 2002 May 24.
Reference Type
BACKGROUND
De Vivo DC, Wang D, Pascual JM, Ho YY. Glucose transporter protein syndromes. Int Rev Neurobiol. 2002;51:259-88. doi: 10.1016/s0074-7742(02)51008-4. No abstract available.
Reference Type
BACKGROUND
Brockmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascual JM, Kuang K, Yang H, Ma L, Kranz-Eble P, Fischbarg J, Hanefeld F, De Vivo DC. Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol. 2001 Oct;50(4):476-85. doi: 10.1002/ana.1222.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UTSW 082013-016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
NCT03301532
COMPLETED
PHASE2
Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome
NCT02000960
UNKNOWN
PHASE2
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT07097311
RECRUITING
PHASE2
Effects of L-Carnitine on Gastric Emptying in Children With Drug Resistant Epilepsy on Ketogenic Diet
NCT06255873
COMPLETED
NA
Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial
NCT02176096
COMPLETED
NA
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
NCT06309251
RECRUITING
Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits
NCT00181090
COMPLETED
PHASE1
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
NCT02216500
RECRUITING
NA
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
NCT05933200
ACTIVE_NOT_RECRUITING
PHASE3
Exogenous Ketone Esters for Refractory Status Epileptics
NCT05674552
RECRUITING
PHASE2/PHASE3
Ketogenic Diet Following Moderate to Severe Pediatric Traumatic Brain Injury
NCT04933448
UNKNOWN
NA
Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery
NCT02571491
COMPLETED
PHASE2
Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.
NCT03059160
UNKNOWN
PHASE2
Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
NCT06700811
RECRUITING
PHASE1
Outcomes of Drug Resistant Epileptic Pediatric Patient by Modified Atkins Diet
NCT07275125
NOT_YET_RECRUITING
The Effect of Carnitine Supplementation on Cardiac Function and Lipid Profile in Patients With Drug Resistant Epilepsy on Ketogenic Diet
NCT06198803
UNKNOWN
EARLY_PHASE1
Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With Phenylketonuria
NCT06901323
ACTIVE_NOT_RECRUITING
PHASE4
A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria
NCT06637514
RECRUITING
PHASE2
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
NCT05756621
RECRUITING
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels
NCT02375828
COMPLETED
PHASE3
Effects of Exogenous Ketone Ester Supplementation on 3-hydroxybutyrate Concentrations in Human Cerebrospinal Fluid
NCT06318299
COMPLETED
NA
Use of Ketamine Prior to Cardiopulmonary Bypass in Children
NCT00556361
COMPLETED
PHASE2
Predictors of Drug Resistant Epilepsy Among Pediatric Patients
NCT07241754
NOT_YET_RECRUITING
Ketogenic Diet for New-Onset Absence Epilepsy
NCT04274179
RECRUITING
PHASE3
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
NCT00892073
COMPLETED
PHASE2